China first mRNA COVID-19 vaccine may start production next month
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
China first mRNA COVID-19 vaccine may start production next month
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
China first mRNA COVID-19 vaccine may start production next month.
The mRNA COVID-19 vaccine was jointly developed by China Academy of Military Medicine of the Academy of Military Sciences, Suzhou Aibo Biotechnology Co., Ltd. and Yunnan Watson Biotechnology Co., Ltd. Yuxi Watson Biotechnology Co., Ltd. is responsible for the construction of the base, and it is expected to produce 200 million doses of vaccine each year.
Recently, China’s first mRNA COVID-19 vaccine production workshop was completed and delivered in Yuxi, Yunnan province.
The mRNA COVID-19 vaccine was jointly developed by the Academy of Military Medicine of the Academy of Military Sciences, Suzhou Aibo Biotechnology Co., Ltd. and Yunnan Watson Biotechnology Co., Ltd. Yuxi Watson Biotechnology Co., Ltd. is responsible for the construction of the base. The total investment of this base is expected to be 520 million yuan. It can produce 200 million doses of vaccine each year and is China first mRNA COVID-19 vaccine industrialization base.
mRNA is a natural molecule that provides instructions to human cells, stimulates the body’s immunity to produce antigens, and fights the corresponding disease.
The mRNA gene encoding the S protein is directly injected into the human body, and the human cell is used to synthesize the S protein in the human body to stimulate the human body to produce antibodies.
In layman’s terms, it is equivalent to handing over a detailed virus file to the body’s immune system.
The mRNA vaccine is currently the vaccine with the highest protection rate (95%) in the results of Phase III clinical trials announced globally.
At the same time, its R&D technology threshold is high. At present, only a few mRNA vaccine varieties developed in the United States and Germany have entered the clinical research stage.
There are several reasons why China is fully promoting mRNA vaccines:.
1. Guarantee of vaccine supply.
The vaccine antigen target selection used in China is more precise, and the neutralizing antibody induced is highly specific.
2. Let the mRNA vaccine be produced in China.
China’s mRNA vaccine core raw materials and equipment have all been made locally, which means that once the production approval is obtained, the production capacity will be able to achieve rapid expansion to meet the supply.
3. It is easier to produce and store.
Chinese-produced mRNA uses a single prefilled injection form, which can be stored at room temperature for a week or at 4°C for a long time. The cold chain cost is low and it is easy to achieve large-scale population vaccination.
At present, in addition to the smooth progress in the development of mRNA vaccines, China’s recombinant vaccines based on traditional technologies are already in the forefront of the world.
According to statistics, up to now, 5 vaccine projects in China have entered phase III clinical trials, and vaccination has been initiated in more than ten countries, and there have been no reports of serious adverse reactions.
(source:internet, reference only)
Disclaimer of medicaltrend.org
